By Fineline Cube 
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao Pengbo unit has initiated a Phase Ib study in mainland China for XH-S004, an oral DPP-1 inhibitor targeting chronic obstructive pulmonary disease (COPD). This follows the asset’s advancement to Phase II trials for non-cystic fibrosis bronchiectasis.
XH-S004 Mechanism and Advantages
XH-S004 works by blocking DPP-1 and the downstream neutrophil serine proteases it activates, thereby reducing chronic airway inflammation and damage. Current COPD treatments primarily rely on bronchodilators and inhaled steroids, which have limited effects on neutrophilic inflammation. Only one type-2-targeted drug has been approved in China over the past two decades. XH-S004 offers a novel approach by potentially reducing exacerbations and slowing disease progression, with no DPP-1 mechanism yet approved globally.
Clinical Development Progress
Fosun Pharma’s XH-S004 has shown promise in preclinical studies and earlier clinical trials. The initiation of the Phase Ib study in COPD represents a significant step forward in the development of this innovative therapy. The company aims to address the significant unmet medical needs in COPD management through this potential breakthrough treatment.-Fineline Info & Tech